http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 주제어 : 시프로플록사신 (검색결과 9 건)
-
분자 각인 실리카 기반 고감도·고선택성 시프로플록사신 전기화학 센서 개발
시프로플록사신(CIP)은 동물 질병 치료에 널리 사용되지만, 남용으로 인해 토양과 수자원이 오염되고 동물성 식품에 축적될 수 있다. 이러한 오염은 약물 내성과 알레르기 반응을 유발하여 인체 건강에 심각한 위협이 된다. 본 연구에서는 CIP를 선택적이고 초고감도로 검출하기 위한 분자 각인 실리카(MIS) 기반 전기화학 센서를 개발하였다. 이 센서는 스크린 프린팅된 전극에 테트라에틸 오르토실리케이트를 실리콘 전구체로 사용하고, 비닐트리에톡시실란 및 (3-머캅토프로필)트리메톡시실란을 기능성 단량체로 활용하여 분자적으로 인식된 실리케이트 박막을 전기 증착하는 방식으로 제작되었다. 개발된 센서는 0.014 µM의 낮은 검출 한계, 0.01–20 µM의 넓은 선형 범위, 높은 선택성, 재현성 및 재사용성을 보였다. 또한 꿀 시료에서 CIP 검출에 성공적으로 적용되었으며, 5% 미만의 상대 표준 편차(RSD)로 우수한 회수율을 기록하여 형광 분광법과 유사한 결과를 얻었다. Ciprofloxacin (CIP) is widely used to treat animal diseases. However, its chronic abuse has led to severe contamination of soil and water resources and its accumulation in animal-derived foods. This contamination can cause adverse effects such as drug resistance and allergic reactions, posing a serious threat to human health. Thus, in this study, a molecularly imprinted silica-based (MIS) electrochemical sensor was designed for the selective and ultra-sensitive detection of CIP in honey. The sensor was fabricated by electrodepositing a molecularly imprinted silicate thin film onto a screen-printed electrode using tetraethyl orthosilicate as the silicon precursor, along with vinyltriethoxysilane and (3-mercaptopropyl) trimethoxysilane as functional monomers, and CIP as the template molecule. The MIS CIP sensor exhibited a low detection limit of 0.014 µM, a linear range of 0.01–20 µM, and high selectivity, reproducibility, and repeatability. The sensor was successfully applied to the determination of CIP in honey, achieving good recoveries with a relative standard deviation (RSD) of less than 5%, comparable to the results obtained using fluorescence spectroscopy analysis.
-
초음파-가시광선 조건 하 Ag6Si2O7/SmFeO3 복합 촉매를 이용한 H2O2의 생성 및 시프로플록사신 광분해 제거 연구
The design of effective bifunctional catalysts for the destruction of refractory pollutants and the production of H2O2 remains a major challenge. In this study, a number of new Ag6Si2O7/SmFeO3 (ASF) heterojunction catalysts were reasonably fabricated through a simple precipitation strategy. The properties of the prepared ASF nanocomposites were confirmed through various characterization analysis. In particular, ASF-1.5 samples show excellent sonophotocatalytic efficiency (94.9%) on 60 min irradiation at an initial ciprofloxacin (CIP) concentration of 10 mg/L, catalytic capacity of 0.6 g/L, US power 400W, pH 5.0, and US frequency of 40 kHz. In addition, the optimized ASF-1.5 sample showed the best H2O2 production rate of 258.5 μM, which was 2.92 times higher than bare Ag6Si2O7. Scavenging experiments demonstrated that ∙OH and h+ are the first reactive oxidized species (ROS) in CIP degradation reactions. The synergistic effects of ultrasound and visible light can then promote the production of reactive oxide species, resulting in good efficiency in CIP degradation and H2O2 generation through ASF-1.5 heterojunction. Furthermore, a potential pathway for CIP degradation and provisional exposure catalytic mechanisms have been established. In summary, this study provided new insights into the rational design of highly effective ASF sonophotocatalysts for innovative energy production and ecological applications.
-
-
최민지 Graduate School, Yonsei University 2025 국내석사
The aim of this study was to design a novel liposome-based ocular drug delivery system containing ciprofloxacin (CIP) for the treatment of bacterial ocular infections such as keratitis. To enhance encapsulation efficiency within the liposomes, Ciprofloxacin-pamoate (CP) hydrophobic ion pair (HIP) was first prepared. Based on foundational research focused on the characterization of the CP HIP complex, the optimal molar ratio of CP ion pair binding was determined. This study investigates the development of a new formulation of pegylated liposomes encapsulating the CP HIP complex for ocular drug delivery. The CP HIP-loaded pegylated liposome (CPPL) appeared as spherical particles under TEM, with a uniform particle size of 72.46 ± 1.29 nm, a PDI of 19.50 ± 2.12%, and a zeta potential of -21.23 ± 0.76 mV. The encapsulation efficiency (EE) of CPPL was significantly enhanced to 73.43 ± 0.99%, more than three times higher than that of ciprofloxacin-loaded pegylated liposomes (CL). This improvement was attributed to the increased hydrophobicity due to the use of DSPE-PEG 2000 and the HIP, resulting in enhanced encapsulation of the drug (CP) within the liposomal bilayer. CPPL demonstrated stable physicochemical properties over 4 weeks at 4°C, 25°C, and 40°C. In vitro release studies showed a sustained release profile, with less than 80% of the drug released over 72 hours, indicating controlled release characteristics. CPPL also exhibited excellent penetration and antibiofilm activity against Pseudomonas aeruginosa biofilms, demonstrating superior antimicrobial effects in various microbial assays. These results suggest that CPPL has the potential to be a promising formulation for the treatment of bacterial ocular infections, overcoming the limitations of current liposomal drug formulations. 이 연구의 목적은 각막염과 같은 세균성 안구 질환 감염 치료를 위한 ciprofloxacin (CIP)을 함유한 새로운 리포좀 기반 안과 약물 전달 시스템을 설계하는 것이었다. 리포좀 내에서의 봉입 효율을 향상시키기 위해, 먼저 Ciprofloxaicn-pamoate (CP) 소수성 이온쌍(HIP)을 준비하였다. CP HIP의 최적 복합화 효율을 나타내는 결합 몰 비율을 선정하고 특징화에 중점을 둔 기초 연구를 바탕으로, CP HIP를 봉입한 페길화된 리포좀의 새로운 제형 개발 응용연구를 진행하였다. CP HIP를 함유한 페길화된 리포좀 (CPPL)은 TEM 분석에서 구형 입자로 났으며, PDI 19.50 ± 2.12 %으로, 72.46 ± 1.29 nm의 균일한 입자크기와 제타전위 -21.23 ± 0.76 mV를 보였다. CPPL의 봉입 효율(EE)은 73.43 ± 0.99%로, CIP을 함유한 페길화 리포좀(CL)보다 3배 이상 증가했다. 이러한 개선은 DSPE-PEG 2000과 HIP 사용으로 인한 소수성 증가로, 리포좀 이중층 내 약물(CP) 봉입 향상의 결과로 해석된다. CPPL은 4 25 40 에서 4주 동안 안정적인 물리화학적 성질을 유지하였다. In vitro 방출 연구 결과, 72시간 동안 약 80 % 미만의 약물이 방출되어 지속적인 방출 프로파일 보였으며, 이는 조절 방출 특성을 나타낸다. CPPL은 또한 녹농균 바이오필름에 대해 우수한 침투력과 항바이오필름 활성을 보였으며, 다양한 미생물 시험에서 탁월한 향균 효과를 나타냈다. 이러한 결과는 CPPL이 세균성 안구 질환 치료를 위한 유망한 제형이 될 가능성을 시사하며, 현재의 리포좀 약물 제형의 한계를 극복할 수 있는 잠재력을 지니고 있음을 보여준다.
-
-
-
Ciprofloxacin이 임파구의 증식과 Interleukin-2 및 Soluble interleukin-2 receptor의 유리에 미치는 영향
Ciprofloxacin is one of the new fluoroquinolones which have a strong bactericidal activities and broad antibacterial spectrum. Due to the great potential for the clinical use of these drugs it is important to investigate any possible positive or negative side effects on the host defense system. We studied to verify the effects of ciprofloxacin on the incorporation of [³H]thymidine, production of interleukin-2 (IL-2), and release of soluble interleukin-2 receptors (IL-2R) in the cultures of phytohemagglutinin stimulated human peripheral lymphocytes for 5 days. After 3 days, After 3 days, [³H]thymidine incorporation was significantly increased in those groups below the 20 ug/ml of ciprofloxacin with dose dependent manner. At 80 ug/ml of ciprofloxacin, however, the [³H]thymidine incorporation was almost completely inhibited all the time. On the other hand, IL-2 assay in culture supernatants shows that ciprofloxacin strongly increase the production of IL-2. After 3 days, IL-2 activity in culture supernatants are 160.7, 93.3, 4.0, and 40.4 IU/ml at concentrations of ciprofloxacin 80, 20, 5, and 1.25 ug/ml respectively, and 2.3 IU/ml that does not contain drug, as measured by enzyme immunoassay. The effect was significant at clinically achievable concentrations (below 5 ug/ml). The release of IL-2R was not affected below the 20 ug/ml of ciprofloxacin, but significantly decreased at 80 ug/ml of ciprofloxacin. These data show that quinolones increased IL-2 synthesis by mononuclear leukocytes and it suggests that the potential usefulness of these antibiotics, not only as antimicrobial agents, but also as modulators of immune responses.
-
Association between Oral Fluoroquinolone Use and Serious Ventricular Arrhythmia
조용일 제주대학교 일반대학원 2017 국내석사
배경: 플루오로퀴놀론은 다양한 감염성 질환을 치료하기 위해 외래에서 흔히 처방되는 항생제이다. 하지만, 경구 플루오르퀴놀론이 심각한 심실성 부정맥의 위험성을 높이는지 여부는 논란이 있다. 방법: 2014년 건강보험심사평가원 입원환자표본자료를 사용하여 2014년 2월 1일부터 2014년 11월 30일까지 후향적 코호트 연구를 진행했다. 외래에서 경구 플루오르와 아목시실린-클라불란산을 처방 받은 추출한 후 ICD-10 코드로 심각한 심실성 부정맥 환자를 확인했다. 누적 발생률을 추정하고, 콕스 비례위험모형을 이용하여 아목시실린-클라불란산과 비교한 경구 플루오로퀴놀론의 심각한 심실성 부정맥 위험비와 95% 신뢰구간을 산출하였다. 결과: 처방 후 1일에서 7일동안 플루오로퀴놀론 사용자의 심각한 심실성 부정맥 누적 발생률은 처방 100만건당 60.1명 이었으며, 아목시실린-클라불란산 사용자는 25.4명이었다. 플루오로퀴놀론은 심각한 아목시실린-클라불란산과 비교하여 심각한 심실성 부정맥과 관련이 있지 않았다. (위험비, 1.56; 95% 신뢰구간, 0.43-5.70). 어느 종류의 플루오로퀴놀론도 아목시실린-클라불란산과 비교하여 심각한 심실성 부정맥과 관련이 있지 않았다. 오플록사신, 레보플록사신, 시프로플록사신의 위험비는 각각 3.93 (95% 신뢰구간, 0.96-16.1), 0.77 (95% 신뢰구간, 0.08-7.29) and 1.02 (95% 신뢰구간, 0.11-9.54)이었다. 결론: 경구 플로오로퀴놀론은 한국의 일반인구 표본자료에서 심각한 심실성 부정맥의 위험을 높이지 않았다. Background: Fluoroquinolones are broad-spectrum antibiotics widely prescribed in the outpatient setting. However, whether oral fluoroquinolone use is associated with the risk of serious ventricular arrhythmia is controversial. Methods: We conducted a retrospective cohort study using the Korean Health Insurance Review and Assessment Service–National Inpatients Sample (HIRA-NIS) from 1 February 2014 to 30 November 2014. We extracted outpatients who were prescribed oral fluoroquinolone and amoxicillin-clavulanate, then we identified serious ventricular arrhythmia using ICD-10 codes. We estimated cumulative incidence, and Cox regression was used to compute the adjusted hazard ratios [HR] and 95% confidence intervals [CI] of serious ventricular arrhythmia associated with fluoroquinolone use compared to amoxicillin-clavulanate. Results: During the 1 to 7 days after the prescription date, the cumulative incidence of serious ventricular arrhythmia was 60.1 per 1 million prescriptions among fluoroquinolone users and 25.4 among amoxicillin-clavulanate users. Fluoroquinolone use was not associated with serious ventricular arrhythmia, when compared with amoxicillin-clavulanate use (HR, 1.56; 95% CI, 0.43-5.70). Furthermore, subgroup analysis showed no association between the type of fluoroquinolone and the risk of serious ventricular arrhythmia compared to amoxicillin-clavulanate. The HRs of ofloxacin, levofloxacin and ciprofloxacin were 3.93 (95% CI, 0.96-16.1), 0.77 (95% CI, 0.08-7.29) and 1.02 (95% CI, 0.11-9.54), respectively. Conclusions: Oral fluoroquinolone use was not associated with an increased risk of serious ventricular arrhythmia in the sample of the general Korean population.
-
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
